DDInter1274 DDInter1676
Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or even death, with the incidence of severe liver damage was shown to be approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Nefazodone {u} (Compound) resembles {v} (Compound) Hydroxyzine
Nefazodone {u} (Compound) resembles {v} (Compound) Trifluoperazine
Nefazodone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cetirizine
Nefazodone {u} (Compound) binds {v} (Gene) CYP3A4
Nefazodone {u} (Compound) upregulates {v} (Gene) SERPINA3
Nefazodone {u} (Compound) palliates {v} (Disease) endogenous depression
Nefazodone {u} (Compound) downregulates {v} (Gene) ADI1
Nefazodone {u} (Compound) causes {v} (Side Effect) Laryngitis
Nefazodone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Nefazodone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Nefazodone (Compound) resembles Hydroxyzine (Compound)
Nefazodone (Compound) resembles Trifluoperazine (Compound)
Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Nefazodone (Compound) binds CYP3A4 (Gene)
Nefazodone (Compound) upregulates SERPINA3 (Gene)
Nefazodone (Compound) palliates endogenous depression (Disease)
Nefazodone (Compound) downregulates ADI1 (Gene)
Nefazodone (Compound) causes Laryngitis (Side Effect)
Nefazodone may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Nefazodone may cause a minor interaction that can limit clinical effects when taken with Bexarotene